Delivery Order SPE2DB22D3401-SPE2DB26FT0HW
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,088.36 to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 15 mg/0.5 mL pens on September 15, 2025. This firm fixed-price, non-set-aside delivery order, which is due for completion by September 16, 2025, represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with the federal government. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of Mounjaro (tirzepatide) 7.5 mg/0.5 mL pens under a firm fixed-price contract valued at $5,132.40. This non-set-aside award, with an ultimate completion date of October 27, 2025, represents a routine pharmaceutical supply transaction to support federal medical procurement needs. The delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 10 mg/0.5 mL pens valued at $13,934.62 on May 6, 2025, with completion scheduled for May 7, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle running through...
- The Defense Logistics Agency awarded a $9,733.61 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Mounjaro (tirzepatide) 5 mg/0.5 ml pens. The contract is non-competitive with no set-aside designation and carries an ultimate completion date of June 27, 2025. AmerisourceBergen will fulfill this delivery order from its corporate office location in Conshohocken, Pennsylvania, serving the federal government's pharmaceutical supply requirements....
- The Defense Logistics Agency awarded a delivery order valued at $1,170.98 to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 12.5 mg/0.5 mL pen injections on August 29, 2025, with completion scheduled for September 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through the federal procurement process. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 15 mg/0.5 mL pens valued at $1,632.54 on October 20, 2025, with completion scheduled for October 21, 2025. This competitively awarded, non-set-aside delivery order uses firm fixed pricing and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a pharmaceutical supply transaction under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 10 mg/0.5 mL pens on August 20, 2025, with a ceiling value of $1,075.33 and an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order was placed without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a widely used diabetes...
- The Defense Logistics Agency awarded a $3,537.17 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Mounjaro (tirzepatide) 5 mg/0.5 mL pens in 0.5 mL unit doses. The contract, which is a non-set-aside competitive award with an ultimate completion date of July 25, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $11,495.12 delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 5 mg/0.5 mL pens on May 27, 2025, with completion scheduled for May 28, 2025. This competitively awarded, firm fixed-price contract requires delivery to the company's facility in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and...
- The Defense Logistics Agency awarded a delivery order valued at $4,252.48 to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 7.5 mg/0.5 mL pen injectors on October 28, 2025, with completion targeted for October 29, 2025. This non-competitive delivery order carries firm fixed pricing and will be performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical federal medical supply vendor, AmerisourceBergen Drug Corp...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB26FT0HWDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 10 mg/0.5 mL pens on October 29, 2025. This competitive, non-set-aside contract has a ceiling value of $9,410.90 with a firm fixed price structure and an ultimate completion date of October 30, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate facility in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary distribution operations. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen supplies an extensive portfolio of medications and medical supplies to support military healthcare systems and other government entities. The Mounjaro order exemplifies the company's role in providing diabetes management therapies and specialty medications through the DLA's pharmaceutical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.4k | 10/29/25 |